The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
Moderna stock surged on Phase 3 mRNA cancer vaccine results with Merck, breaking key moving averages and hitting record RSI.
After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.
Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.
Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to ...
Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...
Shares of Moderna ( MRNA) rose 177% in Wednesday trading, while Merck’s ( MRK) rose some 12%, after the pharma companies ...
The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.
Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a ...
The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results